About precigen inc - PGEN
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
PGEN At a Glance
Precigen, Inc.
20374 Seneca Meadows Parkway
Germantown, Maryland 20876
| Phone | 1-301-556-9900 | Revenue | 9.68M | |
| Industry | Biotechnology | Net Income | -250,642,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 146.726% | |
| Fiscal Year-end | 12 / 2026 | Employees | 160 | |
| View SEC Filings |
PGEN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 135.095 |
| Price to Book Ratio | 70.74 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -12.656 |
| Enterprise Value to Sales | 135.139 |
| Total Debt to Enterprise Value | 0.075 |
PGEN Efficiency
| Revenue/Employee | 60,525.00 |
| Income Per Employee | -1,566,512.50 |
| Receivables Turnover | 2.22 |
| Total Asset Turnover | 0.064 |
PGEN Liquidity
| Current Ratio | 3.089 |
| Quick Ratio | 2.832 |
| Cash Ratio | 2.623 |
PGEN Profitability
| Gross Margin | 37.051 |
| Operating Margin | -1,100.785 |
| Pretax Margin | -2,588.176 |
| Net Margin | -2,588.207 |
| Return on Assets | -165.354 |
| Return on Equity | -571.968 |
| Return on Total Capital | -210.268 |
| Return on Invested Capital | -264.751 |
PGEN Capital Structure
| Total Debt to Total Equity | 470.04 |
| Total Debt to Total Capital | 82.457 |
| Total Debt to Total Assets | 62.757 |
| Long-Term Debt to Equity | 464.607 |
| Long-Term Debt to Total Capital | 81.504 |